X4 Pharmaceuticals (XFOR) EBT (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted EBT of -$23.9 million for Q4 2025, up 19.84% on a QoQ basis from -$29.8 million in Q3 2025, and up 39.53% year-over-year from -$17.1 million in Q4 2024.
X4 Pharmaceuticals (XFOR) EBT (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' EBT history runs 9 years deep, the most recent figure standing at -$23.9 million for Q4 2025.
- Quarterly EBT rose 39.53% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 113.13% YoY) and the FY2025 annual result came in at -$79.2 million, down 113.13% from the prior year.
- EBT was -$23.9 million for Q4 2025 at X4 Pharmaceuticals, up from -$29.8 million in the prior quarter.
- Across five years, EBT topped out at $90.9 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
- A 5-year average of -$20.0 million and a median of -$22.9 million in 2022 frame the typical range for EBT.
- Peak annual rise in EBT reached 263.12% in 2024, while the deepest fall reached 1509.52% in 2024.
- X4 Pharmaceuticals' EBT stood at -$30.2 million in 2021, then grew by 3.69% to -$29.1 million in 2022, then jumped by 34.35% to -$19.1 million in 2023, then sank by 107.17% to -$39.6 million in 2024, then jumped by 39.53% to -$23.9 million in 2025.
- Business Quant data shows XFOR's EBT at -$23.9 million in Q4 2025, -$29.8 million in Q3 2025, and -$25.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 221.65 Mn |
| 10 | X4 Pharmaceuticals | 167.39 Mn | -49.65 Mn | 2.20 Mn | -23.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.85 Mn |
| Jun 30, 2025 | -25.70 Mn |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | -39.56 Mn |
| Sep 30, 2024 | -36.68 Mn |
| Jun 30, 2024 | 90.85 Mn |
| Mar 31, 2024 | -51.75 Mn |
| Dec 31, 2023 | -19.10 Mn |
| Sep 30, 2023 | -2.28 Mn |
| Jun 30, 2023 | -55.70 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.09 Mn |
| Sep 30, 2022 | -21.60 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.94 Mn |
| Dec 31, 2021 | -30.20 Mn |
| Sep 30, 2021 | -20.17 Mn |
| Jun 30, 2021 | -19.63 Mn |
| Mar 31, 2021 | -18.67 Mn |